Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TWT's (Third Wave Technologies') Invader technology sensitivity confirmed:

This article was originally published in Clinica

Executive Summary

Third Wave Technologies' (TWT) RNA Invader technology, claimed to be a cost-effective alternative to PCR, can detect changes in gene expression level as small as 20%, according to an assessment published in the July issue of Nature Biotechnology. The assessment, by TWT (Madison, Wisconsin), also confirmed that Invader assays can routinely detect as few as 6,000 copies of RNA, and can detect a single target sequence in a pool of more than 20,000 sequences of closely related RNA. TWT has licensed the technology to Dade Behring.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT072076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel